Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow-to-Debt Ratio
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow-to-Debt Ratio of 1.29x as of September 2025, meaning its operating cash flow of ₩6.82 Billion could theoretically repay 1% of its total liabilities (₩5.29 Billion) in one year. See Hwail Pharmaceutical Co.Ltd (061250) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hwail Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hwail Pharmaceutical Co.Ltd across 14 annual periods. Also explore Hwail Pharmaceutical Co.Ltd (061250) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year debt coverage analysis for Hwail Pharmaceutical Co.Ltd. For market capitalisation and broader financial context, see Hwail Pharmaceutical Co.Ltd (061250) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.95x | ₩11.63 Billion | ₩12.19 Billion | ▲ +56.8% |
| 2023 | 0.61x | ₩7.02 Billion | ₩11.55 Billion | ▲ +2710.7% |
| 2022 | -0.02x | ₩-233.56 Million | ₩10.02 Billion | ▼ -101.4% |
| 2021 | 1.61x | ₩20.09 Billion | ₩12.49 Billion | ▲ +10321.0% |
| 2020 | -0.02x | ₩-201.69 Million | ₩12.82 Billion | ▼ -108.5% |
| 2019 | 0.18x | ₩3.69 Billion | ₩19.97 Billion | ▼ -42.8% |
| 2018 | 0.32x | ₩7.17 Billion | ₩22.16 Billion | ▼ -0.2% |
| 2017 | 0.32x | ₩8.34 Billion | ₩25.72 Billion | ▼ -2.7% |
| 2016 | 0.33x | ₩9.58 Billion | ₩28.76 Billion | ▲ +299.4% |
| 2015 | -0.17x | ₩-6.90 Billion | ₩41.33 Billion | ▼ -103.2% |
| 2014 | -0.08x | ₩-2.78 Billion | ₩33.85 Billion | ▼ -143.3% |
| 2013 | 0.19x | ₩6.97 Billion | ₩36.71 Billion | ▲ +484.3% |
| 2012 | 0.03x | ₩1.00 Billion | ₩30.92 Billion | ▼ -87.9% |
| 2011 | 0.27x | ₩7.86 Billion | ₩29.24 Billion | — |